Last reviewed · How we verify
Patients receive microporous polysaccharide hemospheres.
Microporous polysaccharide hemospheres are biocompatible particles that promote hemostasis by providing a physical scaffold for blood clotting and platelet aggregation.
Microporous polysaccharide hemospheres are biocompatible particles that promote hemostasis by providing a physical scaffold for platelet aggregation and blood clotting. Used for Intraoperative hemostasis and control of bleeding during surgical procedures.
At a glance
| Generic name | Patients receive microporous polysaccharide hemospheres. |
|---|---|
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Drug class | Topical hemostatic agent |
| Modality | Small molecule |
| Therapeutic area | Surgery/Hemostasis |
| Phase | FDA-approved |
Mechanism of action
These hemospheres are composed of plant-derived polysaccharides with a microporous structure that absorbs blood and concentrates clotting factors and platelets at the wound site, accelerating the natural coagulation cascade. The particles are bioabsorbable and gradually break down as hemostasis is achieved, making them suitable for topical hemostatic applications in surgical settings.
Approved indications
- Surgical hemostasis and bleeding control
Common side effects
- Minimal systemic absorption
- Local tissue reaction
Key clinical trials
- Use of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing Mastectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: